Russell Investments Group Ltd. Grows Position in Sanofi $SNY

Russell Investments Group Ltd. boosted its position in shares of Sanofi (NASDAQ:SNY) by 39.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 535,527 shares of the company’s stock after buying an additional 150,198 shares during the period. Russell Investments Group Ltd.’s holdings in Sanofi were worth $25,277,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mondrian Investment Partners LTD acquired a new stake in shares of Sanofi in the third quarter valued at approximately $171,742,000. Raymond James Financial Inc. raised its position in Sanofi by 81.3% in the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Sanofi by 10,152.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock worth $103,846,000 after purchasing an additional 2,178,647 shares during the period. Victory Capital Management Inc. boosted its stake in Sanofi by 133.3% during the 3rd quarter. Victory Capital Management Inc. now owns 1,413,640 shares of the company’s stock worth $66,681,000 after purchasing an additional 807,767 shares during the period. Finally, NewEdge Advisors LLC increased its stake in Sanofi by 1,853.1% in the second quarter. NewEdge Advisors LLC now owns 731,208 shares of the company’s stock valued at $35,325,000 after purchasing an additional 693,770 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of research reports. TD Cowen reissued a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. UBS Group reiterated a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. HSBC reissued a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Five analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $62.67.

Sanofi Stock Performance

NASDAQ:SNY opened at $43.63 on Friday. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $106.41 billion, a P/E ratio of 12.12, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45. The firm has a 50-day moving average price of $46.94 and a two-hundred day moving average price of $48.28. Sanofi has a twelve month low of $43.34 and a twelve month high of $59.17.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.